CANBRIDGE LIFE SCIENCES CEO, JAMES XUE, PRESENTING AT
CANCER ADVANCED BOSTON AND BOSTON CEO
April 2, 2015, Beijing - James Xue, PhD, MBA, Founder and CEO of CANbridge Life Sciences, is invited to be a anelist at Cancer Advanced Boston 2015 (http://www.bbbiotechconference.com/conference-details.php?id=32) on April 13-14 at at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, MA. Dr. Xue will take part in the panel “Buy or Build to Grow the Pipeline? on April 14th from 3:40pm - 4:20pm.
Dr. Xue has also been invited to attend the Boston CEO Conference 2015, May 26-27 at the Four Seasons Hotel in Boston (http://bbbiotechconference.com/conference-details.php?id=33).
About CANbridge Life Sciences
CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia. CANbridge has an exclusive licensing agreement with U.S.-based Azaya Therapeutics, Inc., to develop and commercialize ATI-1123 in China, for the treatment of non-small cell lung cancer and other solid tumors. CANbridge also has an agreement with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize Caphosol® in China for the prevention and treatment of oral mucositis caused by cancer treatments.
Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.
CANbridge is privately-held and headquartered in Beijing, China. For more on CANbridge Life Sciences, please go to www.canbridgepharma.com. For more information, please contact: firstname.lastname@example.org.